Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cream beat rosacea redness? new study tests it against placebo

NCT ID NCT07521462

Symptom relief Sponsor: ISISPHARMA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 09, 2026 · Updated 5 times

Summary

This study tests whether a special dermocosmetic cream can reduce facial redness and visible blood vessels in people with a common type of rosacea. Fifty adults will apply the cream to one side of their face and a placebo to the other, twice daily for two months, then continue while also receiving laser treatments. Researchers will compare the cream's effects alone and with laser to see if it helps calm redness better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dermocosmetic cream
What this could lead to
If it works, this could offer a safe, non-prescription option to reduce redness and visible blood vessels from rosacea, possibly boosting laser treatment results.
What could go wrong
This is a small, early-stage study with no phase, so results may not be conclusive. The cream is cosmetic, not a drug, so any improvement is likely modest and temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gender: male or female * Age: \> 18 years -Patients with mild to severe erythro-couperotic rosacea (stage 2, 3, or 4 - TRoSA scale, section 2.2.3.1) * Patients wishing to undergo vascular laser treatments for their rosacea * Patients who have provided informed consent Exclusion Criteria: * Pregnant patients or patients with a positive urine pregnancy test at the initial visit * Patients with another condition in the study area. * Patients who have received laser treatment for the same condition within the previous 12 months. * Patients with another form of rosacea (e.g., papules and pustules, ocular rosacea, etc.). * Patients using another anti-redness product on the face during the study. * Patients who have taken photosensitizing treatments during the month prior to study enrollment. * Patients taking or having taken oral isotretinoin within 6 months prior to study enrollment. * Patients enrolled in another study. * Adult patients under a legal guardianship arrangement (guardianship, conservatorship, judicial protection). * Patients not covered by social security.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rosacea subtype 1 (erythematotelangiectatic) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rosacea telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rosacea subtype 1 (erythematotelangiectatic) Rosacea, erythematotelangiectatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Rouen

    RECRUITING

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.